diabetes

DIABETES PIPELINE ANALYSIS – NOVO NORDISK

2017-10-19T23:47:48+00:00

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®,  which is expected to reach $1.2 billion in 2021.11 In the basal category, Novo Nordisk’s Levemir® has long been second to Sanofi’s Lantus, despite steadily increasing share over time. Hoping to break out in this category, in early 2016, Novo Nordisk launched Tresiba®, their next generation basal insulin to compete against Lantus® and Lantus’s successor Toujeo®. This [...]

DIABETES PIPELINE ANALYSIS – NOVO NORDISK2017-10-19T23:47:48+00:00

The Future of Innovation in Heart Failure & Diabetes

2017-07-18T19:29:48+00:00

Move over big pharma. When it comes to improving the lives of patients with chronic diseases like type-2 diabetes and heart failure, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood for pharmaceutical companies.  Traditionally, they spend big advertising dollars to create consumer awareness with the goal of influencing drug choice.  But when it comes to innovation for major chronic conditions like type 2 diabetes and heart disease, pharma companies need a lifeline.   Innovation pipeline is weak There’s nothing really new coming down the pharma pipeline for diabetes or heart disease - I mean [...]

The Future of Innovation in Heart Failure & Diabetes2017-07-18T19:29:48+00:00